PMID: 9549651Apr 29, 1998Paper

Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy

Journal of Clinical Pharmacology
R C SachdeoA Rosenberg

Abstract

Effects of erythromycin on hepatic CYP450 3A4 isozymes can profoundly influence the metabolism of many therapeutic agents. An open-label, randomized, two-period, crossover study was therefore conducted to evaluate the pharmacokinetics of felbamate before and after a concurrent 10-day regimen (333 mg three times daily) of erythromycin. Patients were receiving either 3,000 or 3,600 mg/day felbamate monotherapy for treatment of epilepsy. Mean dose-normalized values for maximum concentration (Cmax) and area under the concentration-time curve (AUC tau) of felbamate were not statistically different in patients taking felbamate as monotherapy than in patients after erythromycin coadministration. Estimates of time to Cmax (tmax), minimum concentration (Cmin), apparent clearance (Cl/kg), average concentration (Cav), and degree of fluctuation (DFss) were likewise unchanged. The incidence of mild and moderate adverse events increased during coadministration of the two drugs. Because patients with epilepsy can not be treated with erythromycin alone, it could not be determined whether the adverse events were attributable to erythromycin or to the combination of the two drugs. Steady-state pharmacokinetic parameters of felbamate were not inf...Continue Reading

References

Nov 1, 1992·Epilepsia·P Klosterskov JensenG P Menge
Dec 1, 1990·British Journal of Clinical Pharmacology·P CrawfordM Orme
Jan 1, 1990·Pharmacology & Therapeutics·F J Gonzalez
Jun 1, 1989·Canadian Journal of Physiology and Pharmacology·P V Turner, K W Renton
Jan 1, 1985·Clinical Pharmacokinetics·T M Ludden
Feb 1, 1985·Archives of Neurology·E CarrancoS Al-Rajeh
Apr 1, 1983·Clinical Pharmacology and Therapeutics·Y Y WongR D Bell
Sep 1, 1995·Clinical Pharmacology and Therapeutics·P ReidenbergM Guillaume
Oct 1, 1995·Clinical Pharmacology and Therapeutics·J A HulsmanJ Nezamis
Nov 1, 1995·Clinical Pharmacology and Therapeutics·V SaanoC C Lin
Jan 1, 1994·Clinical Pharmacokinetics·F J Gonzalez, J R Idle
May 1, 1993·Clinical Pharmacology and Therapeutics·M L WagnerI E Leppik
Aug 1, 1995·Drugs·R Z HarrisJ B Schwartz

❮ Previous
Next ❯

Citations

Apr 22, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Daniela MilosheskaTomaž Vovk
Jan 24, 2002·Therapeutic Drug Monitoring·Houda HachadRene H Levy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Clinical Pharmacology
O PaulsenH I Bengtsson
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
H Scholz, R Noack
British Medical Journal
N R Williams
© 2022 Meta ULC. All rights reserved